|Previous Section||Index||Home Page|
temsirolimus for mantle cell lymphoma relapsed and/or refractory;
bevacizumab for breast cancer;
erlotinib in combination with bevacizumab for advanced or metastatic non-small cell lung cancer;
rituximab for follicular non-Hodgkins lymphoma;
vandetanib for thyroid cancer;
vandetanib for non small cell lung cancer;
trastuzumab for gastric cancer; and
trabectedin for relapsed ovarian cancer.
Mr. Lansley: To ask the Secretary of State for Health (1) when chemotherapy providers will begin returning an agreed dataset on all patients receiving chemotherapy, as referred to in paragraph 4.52 of his Departments Cancer Reform Strategy; what information is captured by the dataset; and if he will make a statement; 
Ann Keen: A small working group is currently scoping the requirements for chemotherapy data alongside a comparison of data items for chemotherapy that are already included within the National Cancer Dataset. Any dataset agreed will also include the requirements of the cancer registration dataset.
Mr. Lansley: To ask the Secretary of State for Health how many patients in each (a) cancer network and (b) strategic health authority area received (i) chemotherapy for small cell lung cancer and (ii) chemotherapy for non-small cell lung cancer in each year since 1997-98. 
As National Statistician, I have been asked to reply to your recent parliamentary question asking how many patients in each (a) cancer network and (b) strategic health authority area received (i) chemotherapy for small cell lung cancer and (ii) chemotherapy for non-small cell lung cancer in each year since 1997-98. 
The latest year for which data are available on the national cancer registry database, which ONS operates on behalf of the Department of Health, is 2005. Tables 1 and 2 show the number of cases of small and non-small cell lung cancer, newly diagnosed in each of the years 1997-2005 in the specified geographical areas, initially receiving chemotherapy. In 55 per cent. of lung cancer cases in the database, either no treatment information was recorded or patients were recorded as having had no treatment. 10 per cent. of cases was recorded as receiving more than one treatment.
|Table: 1 Registrations of newly diagnosed cases of small cell lung cancer( 1) receiving chemotherapy treatment( 2) , by strategic health authority and Cancer Network( 3) , England, 1997-2005|
|(1) Lung cancer is coded to C34 in the International Classification of Diseases Tenth Revision (ICD-10)|
(2) More than one type of treatment was recorded for some cases.
(3) Cancer Network boundaries as at January 2008.
Office for National Statistics
|Next Section||Index||Home Page|